-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MXcANgj75jM0JJBhYPHwTe890XYlK+xCevCeiSJdPsGu7uLJc2SLH4+qcE2VE47b 5pvaqDDh8Bqt8kkx7qMtcA== 0001193125-06-031702.txt : 20060214 0001193125-06-031702.hdr.sgml : 20060214 20060214172243 ACCESSION NUMBER: 0001193125-06-031702 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060214 DATE AS OF CHANGE: 20060214 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Sirgo Mark A CENTRAL INDEX KEY: 0001301715 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: BUSINESS PHONE: 919 510 8542 MAIL ADDRESS: STREET 1: 3100 STONE GAP COURT CITY: RALEIGH STATE: NC ZIP: 27612 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-57907 FILM NUMBER: 06617414 BUSINESS ADDRESS: STREET 1: 2501 AERIAL CENTER PARKWAY STREET 2: SUITE 205 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-653-5160 MAIL ADDRESS: STREET 1: 2501 AERIAL CENTER PARKWAY STREET 2: SUITE 205 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 SC 13G/A 1 dsc13ga.htm AMENDMENT #1 Amendment #1

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

 

BIODELIVERY SCIENCES INTERNATIONAL, INC.

(Name of Issuer)

 

Common Stock, par value $.001

(Title of Class of Securities)

 

 

09060J106

                                (CUSIP Number)                                

 

December 31, 2005

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

x Rule 13d-1(c)

 

¨ Rule 13d-1(d)

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09060J106

 

  1.  

Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

 

            Mark A. Sirgo

    
  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ¨

(b)  ¨

    
  3.  

SEC Use Only

 

    
  4.  

Citizenship or Place of Organization

 

            United States

    

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

  

  5.    Sole Voting Power

 

838,285 shares of Common Stock, which assumes conversion of shares of Series A Preferred Stock and exercise of options to purchase shares of Common Stock

  6.    Shared Voting Power

 

                0

  7.    Sole Dispositive Power

 

838,285 shares of Common Stock, which assumes conversion of shares of Series A Preferred Stock and exercise of options to purchase shares of Common Stock

  8.    Shared Dispositive Power

 

                0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

838,285 shares of Common Stock, which assumes conversion of shares of Series A Preferred Stock and exercise of options to purchase shares of Common Stock

    
10.  

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

            Not Applicable

    
11.  

Percent of Class Represented by Amount in Row (9)

 

6.65% of the class of Common Stock, which assumes conversion of shares of Series A Preferred Stock and exercise of options to purchase shares of Common Stock

    
12.  

Type of Reporting Person (See Instructions)

 

            IN

    

Item 1.

  

(a)

    Name of Issuer:          
         BioDelivery Sciences International, Inc.          
   

(b)

    Address of Issuer’s Principal Executive Offices          
         185 South Orange Avenue, Admin. Building 4, Newark, New Jersey 07103          

Item 2.

  

(a)

    Name of Person Filing:          
         Mark A. Sirgo          
   

(b)

    Address of Principal Business Office or, if none, Residence:          
         3100 Stone Gap Court, Raleigh, North Carolina 27612          
   

(c)

    Citizenship:          
         United States          
   

(d)

    Title of Class of Securities:          
         Common Stock, par value $.001          
   

(e)

    CUSIP Number:          
         09060J106          

Item 3.

   Filing Pursuant to Rules 13d-1(b) or 13d-2(b)c), check whether the person filing is a:     
    None     

Item 4.

    Ownership.          
     Mr. Sirgo is the beneficial owner of 838,285 shares of common stock, or 6.65% of the issued and outstanding common stock of the Issuer. Such beneficial ownership consists of (i) 20,300 shares of common stock, par value $.001; (ii) options to purchase 20,571 shares of common stock, par value $.001; and (iii) 797,414 shares of Series A Preferred Stock which are convertible into shares of common stock on a 1 for 1 basis. The Series A Preferred Stock is eligible for conversion upon FDA approval of the first proposed product of Arius Paharmaceuticals, Inc.          

Item 5.

    Ownership of Five Percent or Less of a Class.     
     Not Applicable     

Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.          
     Not Applicable     

Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
     Not Applicable     

Item 8.

    Identification and Classification of Members of the Group.          
     Not Applicable     

Item 9.

    Notice of Dissolution of Group.          
     Not Applicable     

Item 10.

    Certification.          
     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and wree not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.     

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2006

 

/s/ Mark A. Sirgo

Mark A. Sirgo
 -----END PRIVACY-ENHANCED MESSAGE-----